ArticleJournal of cachexia, sarcopenia and muscle2025
Leptin From Fibro-Adipogenic Progenitor Cells (FAPs) Regulates Masseter Muscle Disuse Atrophy and Ectopic Fat Accumulation.
Article in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Role of Fibro/adipogenic Progenitors (FAPs) in Sarcopenia: Mechanisms and Potential Therapeutic Strategies.Stem cell reviews and reports · 2026Review
- Leptin From Fibro-Adipogenic Progenitor Cells (FAPs) Regulates Masseter Muscle Disuse Atrophy and Ectopic Fat Accumulation.Journal of cachexia, sarcopenia and muscle · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundExcessive fat accumulation in muscles with disuse atrophy may impair muscle physiologic function and exacerbate the progression of atrophy, with causes largely unexplored. Evidence indicates leptin plays a crucial role in regulating skeletal muscle fat metabolism. Masticatory muscle (a special skeletal muscle) atrophy often causes aesthetic and functional problems due to various occlusal factors. This study examines leptin's role and mechanism in masseter muscle disuse atrophy and explores leptin's source.
methodsA C57BL/6J mouse disuse atrophy model was established. The ameliorative role of leptin in masseter muscle lipid accumulation and atrophy and its local sources were explored by injection of exogenous leptin and nilotinib, which specifically induces leptin-producing fibro-adipogenic progenitor cells (FAPs). Transcriptomic sequencing revealed the molecular mechanism of lipid accumulation in the masseter muscle, which was validated by in vitro experiments.
resultsMice with masseter muscle disuse atrophy showed significant fat accumulation (triglycerides, TG: 3.750-fold elevation, p < 0.001). Local leptin injection reduced masseter muscle fat accumulation (TG: 2.330-fold reduction, p < 0.001) and atrophy index (MuRF-1: 2.068-fold reduction, p < 0.05). Transcriptomic analysis revealed downregulated PPAR lipid metabolism pathways, with significant repression of peroxisome proliferator-activated receptor α (PPARα) and consequent phenotypic effects. Leptin significantly upregulated PPARα expression (mRNA: 10.814-fold elevation, p < 0.001; protein: 1.843-fold elevation, p < 0.001). PPARα silencing in C2C12 cells abrogated leptin's lipid-lowering effect (TG: 3.903-fold reduction abolished, p < 0.01). Fluorescence-activated cell sorting (FACS)-isolated FAPs expressed leptin mRNA. Nilotinib-induced FAP apoptosis reduced local leptin expression (1.628-fold reduction, p < 0.05) and exacerbated masseter muscle lipid accumulation and atrophy (MuRF-1: 2.007-fold elevation, p < 0.001).
conclusionDisuse atrophy reduces leptin secreted by FAPs, triggering lipid accumulation that exacerbates muscle degeneration. This reveals the critical regulatory role of FAPs in maintaining masseter muscle homeostasis through leptin-mediated mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.